Back to search
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed/Refractory Multiple Myeloma (RRMM)
Clinicaltrials.gov:
Other:
#64007957MMY4004
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Relapsed/Refractory Multiple Myeloma (RRMM)
Trial type
Observational
Trial phase
N/A
Investigational
product
product
Talquetamab
Teclistamab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
December 18, 2023
Trial end date
July 31, 2026
CT.gov ID
#NCT06285318
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Denmark,
- France,
- Germany,
- Greece,
- Ireland,
- Israel,
- Italy,
- Norway,
- Spain,
- Sweden,
- United Kingdom
Loading...
Enrolling
Aalborg, Denmark, 9100
Enrolling
Thessaloniki, Greece, 54636
Enrolling
Oslo, Norway, 1478
Enrolling
Athens, Greece, 115 28
Enrolling
Thessaloniki, Greece, 546 39
Enrolling
Nantes, France, 44000
Enrolling
Thessaloniki, Greece, 570 10
Enrolling
Lille, France, 59037
Enrolling
Vigo, Spain, 36213
Enrolling
Valencia, Spain, 46010
Enrolling
Ávila, Spain, 05071
Enrolling
Granada, Spain, 18014
Enrolling
Madrid, Spain, 28046
Enrolling
Madrid, Spain, 28006
Enrolling
Toulouse, France, 31100
Enrolling
Ioannina, Greece, 45500
Enrolling
Stockholms, Sweden, 12559
Enrolling
Hanover, Germany, 30459
Enrolling
Athens, Greece, 115 27
Enrolling
Birmingham, United Kingdom, B15 2GW
Enrolling
Gothenburg, Sweden, 413 45
Enrolling
Vejle, Denmark, 7100
Enrolling
Wolverhampton, United Kingdom, WV10 0QP
Enrolling
London, United Kingdom, NW1 2PG
Enrolling
Hamburg, Germany, 20246
Enrolling
Larissa, Greece, 413 34
Enrolling
Alexandroupoli, Greece, 68100
Enrolling
Würzburg, Germany, 97080
Enrolling
Tønsberg, Norway, 3103
Completed
Florence, Italy, 50141
Completed
Aarhus N, Denmark, 8200
Completed
Naples, Italy, 80131
Completed
Trieste, Italy, 34128
Completed
Bolzano, Italy, 39100
Completed
Dublin, Ireland, D18 AK68
Completed
Cork, Ireland, T12 DV56
Completed
Vandœuvre-lès-Nancy, France, 54500
Completed
Palermo, Italy, 90146
Completed
Cork, Ireland, 00000
Completed
London, United Kingdom, SE1 9RT
Completed
Jerusalem, Israel, 9112001
Completed
Paris, France, 75475
Completed
Málaga, Spain, 29603
Completed
Milan, Italy, 20252
Completed
Marseille, France, 13009
Completed
Chemnitz, Germany, 09116
Completed
Nuremberg, Germany, 90419
Completed
Jönköping, Sweden, 551 85
Completed
Odense, Denmark, 5000
Completed
Brindisi, Italy, 72100
Completed
Salerno, Italy, 84098
Completed
Treviso, Italy, 31100
Completed
Verbania, Italy, 28922
Completed
Vicenza, Italy, 36100
Completed
Lecce, Italy, 73100
Completed
Bologna, Italy, 40138
Completed
Milan, Italy, 20121
Completed
Roma, Italy, 65124
Completed
Copenhagen, Denmark, 2100
Completed
Ramat Gan, Israel, 52621
Completed
Dublin, Ireland, D08 NHY1
Completed
Tel Aviv, Israel, 6423906
Completed
Uddevalla, Sweden, 451 98
Completed
Heidelberg, Germany, 69120
Completed
Roma, Italy, 00168
Completed
Dresden, Germany, 01307
Completed
Galway, Ireland, H91 YR71
Completed
Heraklion, Greece, 715 00
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
